Policy & Acquisitions
Mergers & Acquisitions
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Mergers & Acquisitions
Mergers & AcquisitionsAscidian Bets on Exegenesis to Optimize AAV Delivery for RNA Exon EditorsAscidian Therapeutics and Exegenesis Bio have partnered to combine RNA exon editing with AI-enabled AAV capsid discovery.Fact-Checked
Mergers & AcquisitionsPfizer Advances Berobenatide With $1.5B Blackstone DealPfizer has secured up to $1.5 billion in development funding from Blackstone Life Sciences for berobenatide, its investigational monthly GLP-1 receptor agonist for chronic weight management.Fact-Checked
Mergers & Acquisitionsargenx to Acquire UNP, Adding a New Molecular Discovery Platformargenx has agreed to acquire Unnatural Products for up to $1.15 billion, adding macrocyclic peptide discovery to its antibody engineering capabilities.Fact-Checked
Mergers & AcquisitionsBoehringer Ingelheim and China’s Sino Strike $7.4B Oncology DealBoehringer Ingelheim has secured options on six preclinical oncology programs from Sino Biopharmaceutical, expanding its ADC and T-cell engager pipeline through an agreement featuring US$358 million in upfront…Fact-Checked
Mergers & AcquisitionsEvommune Bets on EVO570 and VAV1 Degradation with $1.1B Hinova DealEvommune has secured worldwide rights outside Greater China to Hinova’s investigational oral VAV1 molecular glue degrader EVO570 in a deal worth up to $1.1 billion.Fact-Checked
Mergers & AcquisitionsNxera Licenses IBD Candidate to AbbVie in $1.47B DealNxera Pharma has granted AbbVie exclusive global development and commercialization rights to NXE0033744, an investigational oral EP4 receptor agonist for inflammatory bowel disease.Fact-Checked
Mergers & AcquisitionsBrise Reports Milestone Progress in $757M AbbVie Migraine DealBrise Pharmaceuticals has achieved several near-term milestones under its licensing agreement with AbbVie for two preclinical migraine programmes.Fact-Checked
Mergers & AcquisitionsFresenius Extends Biopharma Growth Beyond 2030 With WuXi DealFresenius has entered an exclusive development agreement with WuXi Biologics for up to 37 potential biosimilar candidates, expanding its marketed and pipeline portfolio from 29 to 66 molecules.…Fact-Checked
Mergers & AcquisitionsBioMarin, GC Biopharma and Hanmi Pharm Sign $475M Fabry Therapy DealBioMarin has secured exclusive worldwide rights outside South Korea to HM15421/GC1134A from GC Biopharma and Hanmi Pharm in a deal worth up to $475 million.Fact-Checked
Mergers & AcquisitionsNovocure to Evaluate TTFields With Verastem’s VS-7375 in Pancreatic CancerNovocure plans to evaluate Tumor Treating Fields therapy with gemcitabine, nab-paclitaxel and Verastem Oncology’s investigational KRAS G12D inhibitor VS-7375 in approximately 25 patients with locally advanced pancreatic cancer.…Fact-Checked
Mergers & AcquisitionsAstellas and Audax Sign US$1.34 Billion Agreement for DAX-044Astellas Pharma and Audax Biosciences have signed an exclusive option and licence agreement for DAX-044, with total potential payments of up to $1.34 billion, excluding royalties.Fact-Checked
Mergers & AcquisitionsTeva Acquires BXCL501, Targeting At-Home Agitation CareTeva Pharmaceutical Industries has acquired worldwide rights to BioXcel Therapeutics’ BXCL501 in a deal worth up to $125 million.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.